

| | |
|--|--|
| Title | Norfolk and Waveney Lipid Hub FH & High-Risk Collaboration |
| Organisations Involved | Amgen Limited and NHS Norfolk and Waveney Integrated Care Board |
| Collaborative Working Project Description | Develop a service to identify patients with FH, enable them to have genetic testing, with a view to developing a cascade testing service to family members. Treat and manage patients effectively through primary and secondary care interventions. |
| Expected Outcomes | <ul style="list-style-type: none"> • Develop a local guideline for identification and treatment of patients • Develop and evaluate an effective process for eventual cascade identification and testing of affected relatives • Map treatment pathway for effective treatment pathway of these patients |
| Actual Outcomes | <p>A pathway for FH has been developed.</p> <p>16 PCNs have been involved in screening with 46 practices taking part.</p> <p>629 patients were contacted of these patients 175 responded and 150 were screened for FH, 141 blood samples were screened.</p> <p>The identification rate was 1:6</p> <p>This high identification rate (nationally 1:25) was noted by Heart UK and this has secured further investment from the ICB which includes a capability to call patients directly from their GP records. The ICB have also automatically included all practices across Norfolk. A practice must actively opt out if they do not want patients screened.</p> <p>The ICB have taken on the support for licencing of the Eclipse Live FH identification system which frees up resource within the Lipid Clinic. This has enabled the CNS FH to start an extra clinic within the service.</p> |

GBR-NP-0225-80005 February 2025